Back to the future: revisiting HIV-1 lethal mutagenesis

Area of Science:

• Virology
• Molecular Biology
• Antiviral Therapy

Background:

• Lethal mutagenesis, a strategy to eliminate viral infectivity by increasing mutation rates, was first proposed for RNA viruses over a decade ago.
• Initially conceptualized as a slow mutation accumulation model for HIV-1 treatment, clinical translation faced challenges due to limited efficacy data with drug leads.
• Recent research has shifted focus towards rapid induction of lethal mutagenesis within a limited number of replication cycles.

Purpose of the Study:

• To explore the potential of lethal mutagenesis as a therapeutic strategy against HIV-1.
• To investigate recent advancements in inducing rapid HIV-1 lethal mutagenesis.
• To address limitations in clinical translation of earlier lethal mutagenesis approaches.

Main Methods:

• Review of recent studies on apolipoprotein B mRNA editing complex 3 (APOBEC3) proteins.
• Analysis of new progress in the use of nucleoside analogs for inducing lethal mutagenesis.
• Evaluation of models for rapid mutation accumulation in HIV-1.

Main Results:

• Recent studies on APOBEC3 proteins have contributed to refocusing attention on HIV-1 lethal mutagenesis.
• Progress in nucleoside analog development shows promise for rapid induction of lethal mutagenesis.
• The rapid mutation accumulation model offers a renewed perspective on overcoming clinical translation hurdles.

Conclusions:

• Lethal mutagenesis remains a viable strategy for combating HIV-1 infection.
• Advances in understanding APOBEC3 proteins and nucleoside analogs are key to developing effective rapid HIV-1 lethal mutagenesis therapies.
• The rapid mutation accumulation model presents a more promising path for clinical translation compared to the slow accumulation model.